- In September 2020, data presented at the ESMO Virtual Congress highlighted findings from the sarcoma cohort of a phase 2 basket study, demonstrating that pembrolizumab monotherapy significantly prolonged progression-free survival (PFS) in specific rare sarcoma subtypes, including epithelioid sarcoma, angiosarcoma, and chondrosarcoma. This study underscores the potential effectiveness of pembrolizumab as a treatment option for these challenging cancer types. The positive results reinforce the importance of targeted therapies in improving outcomes for patients with rare sarcomas
- In December 2020, a study conducted by clinician-scientists at the National Cancer Centre Singapore (NCCS), in collaboration with global research institutions, revealed that angiosarcomas possess distinct genomic and immune profiles. This groundbreaking research led to the classification of angiosarcomas into three specific subtypes. With this new classification system, clinicians can adopt a personalized medicine approach, tailoring treatment strategies to better suit the individual needs of patients based on their specific angiosarcoma subtype
- In April 2022, Novartis announced that the U.S. Food and Drug Administration (FDA) had granted commercial authorization for its state-of-the-art gene therapy manufacturing facility in Durham, North Carolina. Spanning 170,000 square feet, this facility is equipped to manufacture, test, and commercialize Zolgensma, a gene therapy for spinal muscular atrophy. In addition, it will support the production of gene therapy products for ongoing and future clinical trials, significantly enhancing Novartis's capabilities in the field of gene therapy
- In October 2021, Amgen finalized its acquisition of Teneobio, Inc., a transaction valued at $900 million in cash. This acquisition incorporates Teneobio's innovative specific and multispecific antibody technologies, which enhance Amgen's current antibody capabilities and the BITE platform. As a result, this strategic move is expected to significantly accelerate and improve the efficiency of discovering and developing new therapeutic molecules
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, and Immunotherapy), Location of Instigation (Hemangiosarcoma and Lymphangiosarcoma), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Angiosarcoma Treatment Market size was valued at USD 266.00 USD Million in 2023.
The Global Angiosarcoma Treatment Market is projected to grow at a CAGR of 5.1% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
